Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus

American Journal of the Medical Sciences

Volumn 336, Issue 3, 2008, Pages 241-247

  Gosmanova, Elvira O ^b   Canada, Robert B ^b   Mangold, Therese A ^a   Rawls, William N ^a   Wall, Barry M ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c NONE   (United States)

Author keywords

Metformin; Mortality; Sulfonylurea; Type 2 diabetes mellitus

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA; ANGIOTENSIN RECEPTOR ANTAGONIST; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; PROPORTIONAL HAZARDS MODEL; SURVIVAL; VETERAN; AFRICAN AMERICAN; AGE; AGED; BLOOD; CAUCASIAN; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; STATISTICS; UNITED STATES;

AFRICAN AMERICANS; AGE FACTORS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KAPLAN-MEIERS ESTIMATE; MALE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SULFONYLUREA COMPOUNDS; TENNESSEE; UNITED STATES; VETERANS;

EID: 55249097866     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31816250e6     Document Type: Article

References (28)

1. Feinglos MN, Bethel MA. Therapy of type diabetes, cardiovascular death, and the UGDP. Am Heart J 1999;138:S346- S352.
2. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
4. Cryer DR, Nicholas SP, Henry DH, et al. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005;28:539-43.
5. Johnson JA, Majiumdar SR, Simpson SH, et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-8.
6. Johnson JA, Simpson SH, Toth EL, et al. Reduced cardiovascular morbidity and mortality associated with met-formin use in subjects with type 2 diabetes. Diabet Med 2005;22:497-502.
7. Evans JM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49:930-6.
8. Fisman EZ, Tenenbaum A, Benderly M, et al. Antihyper-glycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 1999;91:195-202.
9. Mannucci E, Monami M, Masotti G, et al. All-cause mortality in diabetic patients treated with combinations of sulfonyl-ureas and biguanides. Diabetes Metab Res Rev 2004;20:44-7.
10. Olsson J, Lindberg G, Gottsater M, et al. Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000;43:558-60.
11. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001;24:151-8.
12. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 2004;20:239-45.
13. Banaszewska B, Duleba AJ, Spaczynski RZ, et al. Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. Am J Obstet Gynecol 2006;194:1266-72.
14. Glueck CJ, Aregawi D, Agloria M, et al. Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. Metabolism 2006;55:1582-9.
15. Kleinman JC, Donahue RP, Harris MI, et al. Mortality among diabetics in a national sample. Am J Epidemiol 1988; 128:389-401.
16. Robinson AC, Burke J, Robinson S, et al. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998;21:701-5.
17. Mourao-Junior CA, Sa JR, Guedes OM, et al. Effects of metformin on the glycemic control, lipid profile, and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin. Braz J Med Biol Res 2006;39:489-94.
18. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;CD002966.
19. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.
20. Sasali A, Leahy JL. Is metformin cardioprotective? Diabetes Care 2003;26:243-4.
21. Kahler KH, Rajan M, Rhoads GG, et al. Impact of oral anti-hyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 2007;30:1689-93.
22. Bruno G, Merletti F, Boffetta P, et al. Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus. Diabe-tologia 1999;42:297-301.
23. Sasaki A, Uehara M, Horiuchi N, et al. A 15-year follow-up study of patients with non-insulin-dependent diabetes mellitus (NIDDM) in Osaka, Japan. Factors predictive of the prognosis of diabetic patients. Diabetes Res Clin Pract 1997;36:41-7.
24. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:182-8.
25. Bergenstal R, Johnson M, Whipple D, et al. Advantages of adding metforminto multiple dose insulin therapy in type 2 diabetes. Diabetes 1998;47:A89.
26. Bermudez EA, Rifai N, Buring J, et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002;22:1668-73.
27. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
28. Schaumberg DA, Glynn RJ, Jenkins AJ, et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 2005;111:2446-53.